Although patients with ER+ and/or PR+ breast cancer can benefit from endocrine therapy [4], alternative types of treatment including chemotherapy are often envisaged due to the side effects [13,14,15] and the high risk of post-therapy recurrence [16,17]. This evidence concerns the gene PGR and breast carcinoma.